Xenoport - Best Pharma Stocks of 2007

Company: Xenoport
Starting stock price: $24.38
Ending stock price: $55.88
Percent Change: 129%

Details: Xenoport is developing therapies for central nervous system disorders. It has four clinical stage product candidates: SP13412 for RLS and neuropathic pain; XP19986 for GERD and spasticity; XP21279 for Parkinson's; and XP20925 for migraine and nausea. In addition to reporting strong late-stage results for XP13512 in 2007, the company also inked a $630 million deal with GlaxoSmithKline for rights to the drug.

More News:
Xenoport rallies on positive RLS data. Report
XenoPort inks $630M licensing deal for nerve drug. Report
XenoPort touts IIb data for new RLS therapy. Report

Xenoport - Best Pharma Stocks of 2007

Suggested Articles

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

By extending the tender offer for just six days, Roche seems confident it will receive positive reviews from U.S. and U.K. watchdogs in time.